IBIO Stock Overview
A biotechnology company, engages in the development of precision antibodies in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
iBio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.15 |
52 Week High | US$15.99 |
52 Week Low | US$1.02 |
Beta | -3.36 |
11 Month Change | 2.87% |
3 Month Change | 25.00% |
1 Year Change | -79.33% |
33 Year Change | -99.67% |
5 Year Change | -99.36% |
Change since IPO | -99.95% |
Recent News & Updates
Shareholder Returns
IBIO | US Biotechs | US Market | |
---|---|---|---|
7D | 0.5% | -0.5% | -1.6% |
1Y | -79.3% | 14.9% | 19.8% |
Return vs Industry: IBIO underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: IBIO underperformed the US Market which returned 19.8% over the past year.
Price Volatility
IBIO volatility | |
---|---|
IBIO Average Weekly Movement | 11.0% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: IBIO's weekly volatility has decreased from 31% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 26 | Martin Brenner | www.ibioinc.com |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.
iBio, Inc. Fundamentals Summary
IBIO fundamental statistics | |
---|---|
Market cap | US$20.01m |
Earnings (TTM) | -US$17.13m |
Revenue (TTM) | US$50.00k |
370.8x
P/S Ratio-1.1x
P/E RatioIs IBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IBIO income statement (TTM) | |
---|---|
Revenue | US$50.00k |
Cost of Revenue | US$0 |
Gross Profit | US$50.00k |
Other Expenses | US$17.18m |
Earnings | -US$17.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.99 |
Gross Margin | 100.00% |
Net Profit Margin | -34,258.00% |
Debt/Equity Ratio | 56.4% |
How did IBIO perform over the long term?
See historical performance and comparison